Business Context and Reporting Period
This Form 8-K, dated September 15, 2020, reports the completion of a merger between resTORbio, Inc. (the "Company") and Adicet Bio, Inc. ("Adicet"). Following the merger, the Company changed its name to Adicet Bio, Inc. and its ticker symbol from "TORC" to "ACET" on the Nasdaq Global Market. The combined entity is a biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases.
Key Financial Metrics and Capital Structure
This filing is a current report regarding a corporate transaction and does not contain a full set of financial statements (revenue, profit, or cash flow) for the reporting period. Key capital structure details include:
- Post-Merger Equity: Approximately 19,589,828 shares of common stock outstanding immediately following the merger (post 1-for-7 reverse stock split).
- Ownership Distribution: Former Adicet equityholders hold approximately 75% of outstanding shares on a fully-diluted basis; former resTORbio equityholders hold approximately 25%.
- Exchange Ratio: Each outstanding share of Adicet capital stock was converted into 0.1240 shares of Company Common Stock.
- Debt and Financing:
- Escrow Funding: Investors committed up to $15,000,000 to an escrow account for a concurrent private placement, contingent on a "Qualified Financing" of at least $30,000,000 gross proceeds within 12 months.
- Loan Agreement: The Company assumed Adicet's loan with Pacific Western Bank ("PacWest") and executed an Unconditional Secured Guaranty granting PacWest a security interest in substantially all Company assets (excluding intellectual property).
- Warrants Issued:
- PacWest Warrant: To purchase up to 5,301 shares (plus potential additional shares up to 15,904) at an exercise price of $11.32 per share, expiring April 28, 2027.
- Beech Hill Warrants: To purchase an aggregate of 220,890 shares at an exercise price of $11.32 per share, with expiration dates ranging from July 2026 to September 2026.
Material Changes Versus Prior Period
The filing details a fundamental change in the Company's corporate structure and operations:
- Corporate Identity: The Company changed its name from resTORbio, Inc. to Adicet Bio, Inc. The business focus shifted from resTORbio's previous operations to Adicet's allogeneic gamma delta T cell therapies.
- Capital Structure: A 1-for-7 reverse stock split was effected immediately prior to the merger closing.
- Leadership: The Board of Directors and executive officers were reconstituted. Former resTORbio directors resigned, and Adicet's leadership, including Chen Schor (CEO), Stewart Abbot (CSO/COO), and Francesco Galimi (CMO), assumed executive roles.
- Asset Assumption: The Company assumed Adicet's stock option plans and warrants, adjusted for the exchange ratio.
Guidance, Outlook, Risks, and Contingencies
Contingent Value Rights (CVRs): The Company entered into a CVR Agreement entitling pre-merger stockholders to receive substantially all net proceeds from the commercialization of RTB101 (a TORC1 inhibitor for COVID-19) if licensed to a third party. These rights are not transferable or listed on an exchange.
Financing Contingency: The $15,000,000 escrow funding is contingent upon the Company consummating a Qualified Financing of at least $30,000,000 within 12 months of the merger closing. If this fails, the funds will be returned to investors.
Risk Factors: The filing incorporates by reference Adicet Therapeutics, Inc.'s Risk Factors, Management's Discussion and Analysis, and Business Section (Exhibits 99.2, 99.3, and 99.4), which detail risks associated with clinical development, regulatory approval, and financial liquidity.
Important Facts for Investor Verification
- Verify the status of the "Qualified Financing" required to unlock the $15,000,000 escrow funding within the 12-month window.
- Review the terms of the Unconditional Secured Guaranty granted to PacWest, which covers substantially all Company assets excluding intellectual property.
- Monitor the commercialization progress of RTB101 to assess the potential value of the Contingent Value Rights (CVRs) held by pre-merger stockholders.
- Confirm the dilution impact of the newly issued warrants to PacWest and Beech Hill Securities (aggregate of ~226,000+ shares at $11.32 exercise price).
- Examine the audited and unaudited financial statements of Adicet Therapeutics, Inc. filed as Exhibits 99.5 and 99.6 to assess the acquired entity's financial health.